Skip to content
Clinical Trials – home

Centro Hospitalar Universitario De Santo Antonio E.P.E.

Verified siteinfo

Portugal Largo Professor Abel Salazar, 4050-011 Porto, Portugal

  • 74 trials recruiting
  • Non-small cell lung cancer · Dermatitis atopic · Crohn's disease
  • Adults and children

About Specializations

Centro Hospitalar Universitario De Santo Antonio E.P.E. in Porto, Portugal specialises in clinical trials of conditions such as Non-small cell lung cancer, Dermatitis atopic, Crohn's disease, Hidradenitis, and other specialisations. This site conducts important research.

Main research areas of the site

Nervous System Diseases

The Centro Hospitalar Universitario De Santo Antonio pediatric neurology team is studying Migraine in children, testing a new biologic therapy to reduce the number of migraine days and improve daily functioning.

  • Evaluation of a novel preventive treatment
  • Assessment of attack frequency reduction
  • Monitoring safety and tolerability in young patients
  • Impact on quality of life and school attendance
  • Long‑term follow‑up of therapeutic outcomes

With 73 investigators involved, the site in Porto, Portugal, is leading five independent trials aimed at advancing care for pediatric migraine sufferers.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Largo Professor Abel Salazar4050-011 PortoPortugal
Recruiting now
74 trials
Conditions studied
138
Partner status
Verified site

More sites in PortoPortugal

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

188 clinical trials

Countries:PortugalPortugal
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC

A study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.

A Study Comparing Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Vitiligo

Recruiting

Study of ruxolitinib cream for children aged 6 to 12 years with non-segmental vitiligo

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Breast cancer

Recruiting

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan vs. Palbociclib-Based Drug Combination for Advanced HR-Positive, HER2-Low Breast Cancer Patients

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Medica Scientia Innovation Research S.L.

Study on Spesolimab for Adults with Pyoderma Gangrenosum Requiring Systemic Therapy

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Leo Pharma A/S

Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Seagen Inc.

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

A Study of Baricitinib to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

A Study of Baricitinib to Delay Type 1 Diabetes in Children and Adults at Risk of Developing the Disease

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.